<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="846">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150145</url>
  </required_header>
  <id_info>
    <org_study_id>E-SCLC-liver001</org_study_id>
    <nct_id>NCT05150145</nct_id>
  </id_info>
  <brief_title>Radiotherapy or Observation of Liver Metastases in Small Cell Lung Cancer</brief_title>
  <official_title>A Prospective Phase II Randomized Clinical Study of Radiotherapy or Observation of Liver Metastases for Small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guizhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized study is to investigate local tumor control,survival outcomes and&#xD;
      complications on patients of liver metastasis in small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Small cell lung cancer (SCLC) is a kind of disease with high degree of malignancy and poor&#xD;
      prognosis.Based on the effectiveness of systemic chemotherapy, the treatment of primary&#xD;
      lesions and whole brain radiotherapy can bring survival benefits to patients with extensive&#xD;
      stage small cell lung cancer.Patients with liver metastasis have a worse prognosis than those&#xD;
      with other organ metastases.Local radiotherapy for patients with liver metastasis may have a&#xD;
      better prognosis.However, clinical data of the safety and efficacy of whole liver&#xD;
      radiotherapy for liver metastasis are still lacking.The purpose of this prospective study is&#xD;
      to evaluate the safety, efficacy, and tolerability of liver metastatic radiotherapy in small&#xD;
      cell lung cancer (SCLC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic progression -free survial(Intrahepatic-PFS)</measure>
    <time_frame>UP to 5years</time_frame>
    <description>Intrahepatic progression -free survial is defined as the duration of time from start of treatment to time of progression of hepatic metastasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>UP to 5years</time_frame>
    <description>Overall survival is defined as the time interval from date of diagnosis to date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>UP to 5years</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of progression or death,whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events(toxicities)</measure>
    <time_frame>UP to 5years</time_frame>
    <description>The descriptions and grading scales found in the revised Common Terminology Criteria for Adverse Events(CTCAE 4.0) will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Radiotherapy; Complications</condition>
  <arm_group>
    <arm_group_label>Radiotherpy will be performed to thoracic and liver metastasis.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy for liver metastases and thoracic will be performed in paticipants with liver metastasis who achieved CR or PR after chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherpy will be performed to thoracic.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Radiotherapy performed only on the thoracic after chemotherapy of paticipants with liver metastasis who achieved CR or PR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherpy will be performed to thoracic and liver metastasis after chemotherapy.</intervention_name>
    <description>Intensity modulated radiotherapy will be performed to liver metastasis and thoracic SCLC patients who achieved CR or PR after chemotherapy .</description>
    <arm_group_label>Radiotherpy will be performed to thoracic and liver metastasis.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Informed consent (radiation, medication) before treatment;&#xD;
&#xD;
          2. Age 18 to 70 years old,regardless of gender;&#xD;
&#xD;
          3. Initial SCLC confirmed by histopathological or cytological examination;&#xD;
&#xD;
          4. Metastatic lesions in the distant area: included liver metastasis；&#xD;
&#xD;
          5. Physical status score ECOG: 0 to 2；&#xD;
&#xD;
          6. The expected survival time is more than 3 months;&#xD;
&#xD;
          7. Bone marrow function:hemoglobin(HGB)&gt;90g/L,platelet(PLT)&gt;100×109/L,neutrophil&#xD;
             cell(WBC)&gt;1.5×109/L(*normal value);&#xD;
&#xD;
          8. Liver function:alanine aminotransferase(ALT) and aspertate aminotransferase(AST)&lt;1.5&#xD;
             times of the upper limit of normal(ULN);Total bilirubin &lt;1.5ULN;&#xD;
&#xD;
          9. Renal function:Serum creatinine was lower than 1.5ULN,and the endogenous creatinine&#xD;
             clearance rate(Ccr) is higher than 55mL/min;&#xD;
&#xD;
         10. Initial treatment (previously did not receive any thoracic radiotherapy or surgery).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with history of mental illness;&#xD;
&#xD;
          2. patients combined with other malignancies;&#xD;
&#xD;
          3. Active period of disease caused by bacteria, fungi or viruses; and these severe&#xD;
             infection requiring intravenous antibiotics,antifungal or antiviral therapy;&#xD;
&#xD;
          4. Patients with serious cardiovascular disease ,including uncontrolled hypertension,&#xD;
             unstable angina,history of myocardial infarction within the past 12 months,and severe&#xD;
             arrhythmias.&#xD;
&#xD;
          5. Patients with poorly controlled diabetes who are judged to be unfit for chemotherapy&#xD;
             by doctors.&#xD;
&#xD;
          6. History of hepatitis and cirrhosisi ;&#xD;
&#xD;
          7. pregnant, lactating patients;&#xD;
&#xD;
          8. Patients with poor compliance；&#xD;
&#xD;
          9. Researchers believe that it is not appropriate to participate in this test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengfa Su, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Hospital of Guizhou Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The affiliated hospital of Guizhou medical university</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 28, 2021</last_update_submitted>
  <last_update_submitted_qc>November 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy;liver metastases;Small cell lung cancer;</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

